PABPC1L2B: A RNA-Binding Motif Protein as a Drug Target and Biomarker

Target Name: PABPC1L2B

NCBI ID: G645974

PABPC1L2B

PABPC1L2B: A RNA-Binding Motif Protein as a Drug Target and Biomarker

Abstract:

PABPC1L2B (RNA-binding motif protein 32) is a protein that has been identified as a potential drug target and biomarker. It is a member of the PABPC1L2 family, which is known for its role in various cellular processes, including cell signaling, chromatin structure, and RNA-binding. In this article, we will provide an overview of PABPC1L2B, its function, and its potential as a drug target and biomarker.

Introduction:

PABPC1L2B is a protein that was identified as a potential drug target and biomarker. It is a member of the PABPC1L2 family, which is known for its role in various cellular processes, including cell signaling, chromatin structure, and RNA-binding. PABPC1L2B is expressed in various tissues and cells, including brain, heart, and cancer cells. It has been shown to play a role in various cellular processes, including cell signaling, gene expression, and cell survival.

Function and Potential Therapeutic Applications:

PABPC1L2B is a non-coding RNA-binding protein that can interact with various RNA molecules, including microRNAs and long non-coding RNAs (lncRNAs). It has been shown to play a role in regulating gene expression and cell signaling. PABPC1L2B can interact with various RNA-binding proteins, including silencing elements (RNA-protein interactions) and promoter enhancers (RNA-protein interactions).

PABPC1L2B has been shown to be involved in various cellular processes, including cell signaling, gene expression, and cell survival. It has been shown to play a role in the regulation of cell proliferation, cell survival, and neurodegeneration. PABPC1L2B has also been shown to be involved in the regulation of cell migration and the development of cancer.

PABPC1L2B has been identified as a potential drug target due to its involvement in various cellular processes that are associated with human diseases. For example, PABPC1L2B has been shown to be involved in the regulation of cancer cell migration and the development of neurodegeneration. It has also has been shown to be involved in the regulation of cell signaling and gene expression, which are associated with various human diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

PABPC1L2B can also be used as a biomarker for various diseases. For example, PABPC1L2B has been shown to be downregulated in various human diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. It has also been shown to be upregulated in various healthy tissues, including brain and heart.

Methods:

PABPC1L2B has been shown to interact with various RNA-binding proteins, including silencing elements and promoter enhancers. It has also been shown to play a role in regulating cell signaling, gene expression, and cell survival. To study the function of PABPC1L2B, researchers have used various techniques, including yeast transfection, co-transfection and co-precipitation experiments, RNA interference, Gene overexpression technology, etc.

Conclusion:

PABPC1L2B is a protein that has been identified as a potential drug target and biomarker. It is a member of the PABPC1L2 family, which is known for its role in various cellular processes, including cell signaling, chromosome structure, and RNA-binding. PABPC1L2B is expressed in various tissues and cells, including brain, heart, and cancer cells. It has been shown to play a role in various cellular processes, including cell signaling, gene expression, and cell survival. PABPC1L2B has also been shown to be involved in the regulation of cell migration, the development of cancer,

Protein Name: Poly(A) Binding Protein Cytoplasmic 1 Like 2B

The "PABPC1L2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPC1L2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets